-
美国《脑卒中防治指南》指出,H型高血压是指血浆同型半胱氨酸(homocysteine,Hcy)高于10 μmol/L的原发性高血压[1]。根据这一定义,中国H型高血压在高血压病人中占比高达75%。有研究[9]指出,H型高血压病人伴发心脑血管事件的概率较非H型高血压者明显升高,为病人及家庭带来极大负担。因此,对该病的预防及控制具有重要意义。本研究对不同基因型的H型高血压病人血压和血浆Hcy水平进行比较,并在常规应用降压药物的基础上,给予叶酸作为补充治疗,分析叶酸对其影响,旨在为H型高血压的临床治疗提供依据。现作报道。
-
MTHFR 677C/T基因型检测结果显示,观察组H型高血压病人中以TT基因型为多见,TT组50例(49.02%),其次为CT组28例(27.45%),CC组24例(23.53%);对照组基因分型中TT型13例(43.33%),CT型10例(33.33%),CC型7例(23.33%)。各组病人性别、年龄、病程和吸烟史、饮酒史差异均无统计学意义(P>0.05)(见表 1)。
分组 n 男 女 年龄/岁 病程/年 吸烟史 饮酒史 对照组 30 19 11 55.13±9.80 5.89±1.14 9 5 观察组 TT组 50 31 19 56.07±11.14 5.95±1.05 19 12 CT组 28 20 8 54.97±12.06 6.14±1.46 10 6 CC组 24 13 11 57.96±10.37 6.37±1.55 7 7 F — 1.68* 0.50 0.91 0.86* 1.27* P — >0.05 >0.05 >0.05 >0.05 >0.05 MS组内 — — 2.049 1.538 — — *示χ2值 表 1 各组病人一般资料比较
($\overline{x}\pm s $) -
治疗前,CC组、CT组SBP均明显高于TT组和对照组(P < 0.01);各组病人DBP间差异无统计学意义(P>0.05)。治疗后,对照组和观察组各组病人SBP、DBP均较治疗前下降(P < 0.05);CC组、CT组SBP下降幅度均明显大于TT组和对照组(P < 0.01);观察组各组DBP下降幅度均大于对照组(P < 0.05),CC组DBP下降幅度亦大于TT组(P < 0.05)(见表 2)。
分组 n SBP/mmHg DBP/mmHg 治疗前 治疗后 差值 治疗前 治疗后 差值 对照组 30 154.09±9.13 136.24±13.14△ 11.14±2.15 101.14±11.49 88.90±10.25△ 8.56±2.02 观察组 TT组 50 155.36±10.47 138.79±15.47△ 10.68±3.14 95.97±10.25 78.97±12.36△ 11.35±3.25* CT组 28 169.79±11.54**## 135.97±14.76△ 21.25±4.24**## 97.69±12.94 76.69±13.53△ 12.05±3.47* CC组 24 174.35±20.94**## 132.96±14.38△ 23.97±5.47**## 103.95±14.85 75.33±14.38△ 13.96±4.11*# F — 20.14 1.26 94.38 4.15 10.87 8.13 P — < 0.01 >0.05 < 0.01 >0.05 < 0.05 < 0.05 MS组内 — 187.525 214.658 17.068 132.465 165.427 15.099 q检验:与对照组比较*P < 0.05,**P < 0.01;与TT组比较#P < 0.05,##P < 0.01。配对t检验:与本组治疗前比较△P < 0.05 表 2 各组病人治疗前后血压水平变化比较
($\overline{x}\pm s $) -
治疗前,TT组血浆Hcy水平均明显高于CT组、CC组和对照组(P < 0.01),CT组与CC组血浆Hcy水平差异无统计学意义(P>0.05)。治疗后,各组Hcy水平间差异无统计学意义(P>0.05),观察组各组和对照组病人血浆Hcy水平均较治疗前明显降低(P < 0.01),TT组Hcy水平下降幅度均大于CT组、CC组和对照组(P < 0.01)(见表 3)。
分组 n 治疗前 治疗后 差值 对照组 30 24.54±5.06** 17.83±4.18△△ 6.76±2.26** 观察组 TT组 50 39.89±12.84 17.57±5.13△△ 12.05±3.25 CT组 28 25.97±7.14** 16.16±4.96△△ 6.97±2.14** CC组 24 25.15±6.90** 16.33±5.01△△ 7.14±2.33** F — 30.62 0.91 37.68 P — < 0.01 >0.05 < 0.01 MS组内 — 110.930 24.651 9.894 q检验:与TT组比较**P < 0.01;配对t检验:与本组治疗前比较△△P < 0.01 表 3 各组病人治疗前后血浆Hcy水平变化比较
($\overline{x}\pm s $;μmol/L)
不同基因型H型高血压病人血压和血浆同型半胱氨酸水平比较及补充叶酸对其的影响
Comparison of the blood pressure and plasma homocysteine levels in patients with different genotypes of H-type hypertension, and effects of folic acid supplementation
-
摘要:
目的分析不同基因型H型高血压病人血压和血浆同型半胱氨酸(Hcy)水平及补充叶酸对其的影响。 方法选取行常规降压治疗和叶酸治疗的H型高血压病人102例(观察组),根据不同基因分型进行分组,其中突变型为TT组,杂合型为CT组,野生型为CC组。另选取同期仅进行常规降压治疗未进行叶酸治疗的H型高血压病人30例作为对照组。比较各组病人叶酸治疗前后血压及血浆Hcy水平变化情况。 结果基因型检测结果显示,观察组102例病人中TT组50例(49.02%),CT组28例(27.45%),CC组24例(23.53%)。对照组基因分型中TT型13例(43.33%),CT型10例(33.33%),CC型7例(23.33%)。治疗前,CC组、CT组收缩压(SBP)均明显高于TT组和对照组(P < 0.01),各组病人舒张压(DBP)间差异无统计学意义(P>0.05);治疗后,对照组和观察组各组病人SBP、DBP均较治疗前下降(P < 0.05),CC组、CT组SBP下降幅度均明显大于TT组和对照组(P < 0.01),观察组各组DBP下降幅度均大于对照组(P < 0.05),CC组DBP下降幅度亦大于TT组(P < 0.05)。治疗前,TT组血浆Hcy水平均明显高于CT组、CC组和对照组(P < 0.01),CT组与CC组血浆Hcy水平差异无统计学意义(P>0.05);治疗后,各组Hcy水平间差异无统计学意义(P>0.05),观察组各组和对照组病人血浆Hcy水平均较治疗前明显降低(P < 0.01),TT组Hcy水平下降幅度均大于CT组、CC组和对照组(P < 0.01)。 结论不同基因型的H型高血压病人血压及血浆Hcy水平存在一定差异,在常规降压药物治疗的同时补充叶酸,有助于进一步改善血压和血浆Hcy水平。 -
关键词:
- 高血压 /
- 叶酸 /
- 同型半胱氨酸 /
- 血压 /
- MTHFR 677C/T基因型
Abstract:ObjectiveTo analyze the blood pressure and plasma homocysteine(Hcy) levels in patients with different genotypes of H-type hypertension, and effects of folic acid supplementation on it. MethodsOne hundred and two H-type hypertension patients treated with routine antihypertension and folic acid therapy(treatment group) were subdivided into the TT group, CT group and CC group according to the genotypes.At the same time, 30 H-type hypertension patients treated with routine antihypertension and without folic acid were set as the control group.The blood pressure and plasma Hcy levels were compared among these groups before and after folic acid treatment. ResultsThe genotype test in treatment group showed that there were 50 cases(49.02%) in TT group, 28 cases(27.45%) in CT group and 24 cases (23.53%) in CC group.In the control group, 13 cases were TT type(43.33%), 10 cases were CT type(33.33%), and 7 cases were CC type(23.33%).Before treatment, the systolic blood pressure(SBP) level in CC group was significantly higher than that in TT group and control group(P < 0.01), but there was no statistical significance in the levels of diastolic blood pressure(DBP) among all groups(P>0.05). After treatment, the levels of SBP and DBP in treatment group and control group decreased compared with before treatment(P < 0.05), the decreasing degrees of SBP in CC group and CT group were significantly greater than those in TT group and control group, the decreasing degree of DBP level in observation group was greater than that in control group(P < 0.05), and the decreasing degree of DBP level in CC group was greater than that in TT group(P < 0.05).Before treatment, the plasma level of Hcy in TT group was higher than that in CT group, CC group and control group(P < 0.01), and the difference of the serum level of Hcy between CT group and CC group was not statistically significant(P>0.05).After treatment, there was no statistical significance in the level of Hcy among all groups(P>0.05), the levels of Hcy in observation group and control group significantly decreased compared with before treatment(P < 0.01), and the decreasing degree of the level of Hcy in TT group was greater than that in CT group, CC group and control group(P < 0.01). ConclusionsThere are some differences in blood pressure and plasma Hcy levels in patients with different genotypes of H-type hypertension.The folic acid supplementation combined with conventional antihypertensive drug therapy can further improve the blood pressure and plasma Hcy levels. -
Key words:
- hypertension /
- folic acid /
- homocysteine /
- blood pressure /
- MTHFR 677C/T genotype
-
表 1 各组病人一般资料比较
( )$\overline{x}\pm s $ 分组 n 男 女 年龄/岁 病程/年 吸烟史 饮酒史 对照组 30 19 11 55.13±9.80 5.89±1.14 9 5 观察组 TT组 50 31 19 56.07±11.14 5.95±1.05 19 12 CT组 28 20 8 54.97±12.06 6.14±1.46 10 6 CC组 24 13 11 57.96±10.37 6.37±1.55 7 7 F — 1.68* 0.50 0.91 0.86* 1.27* P — >0.05 >0.05 >0.05 >0.05 >0.05 MS组内 — — 2.049 1.538 — — *示χ2值 表 2 各组病人治疗前后血压水平变化比较
( )$\overline{x}\pm s $ 分组 n SBP/mmHg DBP/mmHg 治疗前 治疗后 差值 治疗前 治疗后 差值 对照组 30 154.09±9.13 136.24±13.14△ 11.14±2.15 101.14±11.49 88.90±10.25△ 8.56±2.02 观察组 TT组 50 155.36±10.47 138.79±15.47△ 10.68±3.14 95.97±10.25 78.97±12.36△ 11.35±3.25* CT组 28 169.79±11.54**## 135.97±14.76△ 21.25±4.24**## 97.69±12.94 76.69±13.53△ 12.05±3.47* CC组 24 174.35±20.94**## 132.96±14.38△ 23.97±5.47**## 103.95±14.85 75.33±14.38△ 13.96±4.11*# F — 20.14 1.26 94.38 4.15 10.87 8.13 P — < 0.01 >0.05 < 0.01 >0.05 < 0.05 < 0.05 MS组内 — 187.525 214.658 17.068 132.465 165.427 15.099 q检验:与对照组比较*P < 0.05,**P < 0.01;与TT组比较#P < 0.05,##P < 0.01。配对t检验:与本组治疗前比较△P < 0.05 表 3 各组病人治疗前后血浆Hcy水平变化比较
( ;μmol/L)$\overline{x}\pm s $ 分组 n 治疗前 治疗后 差值 对照组 30 24.54±5.06** 17.83±4.18△△ 6.76±2.26** 观察组 TT组 50 39.89±12.84 17.57±5.13△△ 12.05±3.25 CT组 28 25.97±7.14** 16.16±4.96△△ 6.97±2.14** CC组 24 25.15±6.90** 16.33±5.01△△ 7.14±2.33** F — 30.62 0.91 37.68 P — < 0.01 >0.05 < 0.01 MS组内 — 110.930 24.651 9.894 q检验:与TT组比较**P < 0.01;配对t检验:与本组治疗前比较△△P < 0.01 -
[1] WEBER GJ, PUSHPAKUMAR S, TYAGI SC, et al.Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension[J].Pharmacol Res, 2016, 113(Pt A):300. [2] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志, 2011, 39(7):579. doi: 10.3760/cma.j.issn.0253-3758.2011.07.002 [3] 徐萍芳, 宋丽娟, 姜衡, 等.缬沙坦联合叶酸在社区老年H型高血压患者中的疗效观察[J].蚌埠医学院学报, 2015, 40(6):727. [4] TANG Z, XIAO L, WANG JQ, et al.Analysis of metabolism-related indicators and MTHFR gene polymorphism in patients with H-type hypertension[J].Minerva Med, 2017, 108(2):103. [5] MA L, LI L, TANG Z.Epidemiological characteristics of hyperhomocysteinemia and H-type hypertension in the elderly in Beijing, China[J].Clin Exp Hypertens, 2017, 39(7):640. doi: 10.1080/10641963.2017.1306540 [6] 朱静.马来酸依那普利叶酸片治疗H型高血压的疗效探讨[J].蚌埠医学院学报, 2017, 42(6):740. [7] 杜丹, 孙明袆, 汲泓, 等.叶酸治疗对老年H型高血压患者同型半胱氨酸水平和动脉粥样硬化的影响[J].河北医学, 2017, 23(1):79. [8] YUAN M, WANG B, TAN S.Mecobalamin and early functional outcomes of ischemic stroke patients with H-type hypertension[J].Rev Assoc Med Bras (1992), 2018, 64(5):428. doi: 10.1590/1806-9282.64.05.428 [9] 白艳.叶酸联合阿托伐他汀对H型高血压患者颈总动脉内膜中层厚度的影响[J].河北医学, 2018, 24(6):955. doi: 10.3969/j.issn.1006-6233.2018.06.019 [10] PANG H, HAN B, FU Q, et al.Association of high homocysteine levels with the risk stratification in hypertensive patients at risk of stroke[J].Clin Ther, 2016, 38(5):1184. doi: 10.1016/j.clinthera.2016.03.007 [11] 陈明友.急性脑梗死患者血清胱抑素C、同型半胱氨酸及血脂水平的变化[J].实用临床医药杂志, 2017, 21(3):181. [12] YE Z, WANG C, ZHANG Q, et al.Prevalence of homocysteine-related hypertension in patients with chronic kidney disease[J].J Clin Hypertens (Greenwich), 2017, 19 (2):151. doi: 10.1111/jch.12881 [13] 张秀洲, 刘福艳, 李静, 等.叶酸干预对H型老年高血压患者血浆同型半胱氨酸水平和主要心血管事件的影响[J].中国基层医药, 2015, 22(9):1327. [14] PANG H, HAN B, FU Q, et al.Association between homocysteine and conventional predisposing factors on risk of stroke in patients with hypertension[J].Sci Rep, 2018, 8(1):3900. [15] 弓园芳, 施梦丽, 张勤, 等.血管性痴呆患者MTHFR基因多态性和血浆Hcy水平检测[J].郑州大学学报(医学版), 2016, 51(5):647. [16] 杨争春, 张志恩, 刘耀晖, 等.马来酸依那普利叶酸片治疗H型高血压的疗效观察及对患者血清同型半胱氨酸水平的影响[J].中国基层医药, 2017, 24(10):1511. doi: 10.3760/cma.j.issn.1008-6706.2017.10.019